#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr

#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those: 💠SLEDAI=>10 💠dsDNA+ve + ⬇️C3 and/ ⬇️C4 💠⬇️C3 and/ C4 pre-treatment 💠Response high regardless SDI, Steroid, #lupus duration @RheumNow https://t.co/fLggazbRQu

MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56

• EULAR Abstract Archive

NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

• EULAR Abstract Archive

Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186: 👉no unexpected AEs; rate of AEs⬇️over time 👉COVID19 seen in 12 controls, 7 VCS 👉4 deaths w/control arm vs 0 deaths w/ VCS 👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow

Immune Checkpoint Inhibitor Associated Arthritis Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk

• https://bit.ly/3GAkgC5

ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow